Xeris Pharmaceuticals Inc. (XERS) Misses Q1 EPS by 4c, provides guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q1 EPS of ($0.14), $0.04 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $40.6 million versus the consensus estimate of $41.46 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2024 revenue of $175-200 million, versus the consensus of $184.4 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• FuelCell Energy signs deal with Fit Energy for up to 380 MW of power